(NASDAQ: KTRA) Kintara Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.15%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.77%.
Kintara Therapeutics's revenue in 2023 is $0.On average, 1 Wall Street analysts forecast KTRA's revenue for 2023 to be $32,902,990, with the lowest KTRA revenue forecast at $32,902,990, and the highest KTRA revenue forecast at $32,902,990. On average, 1 Wall Street analysts forecast KTRA's revenue for 2024 to be $152,335,484, with the lowest KTRA revenue forecast at $152,335,484, and the highest KTRA revenue forecast at $152,335,484.
In 2025, KTRA is forecast to generate $375,268,320 in revenue, with the lowest revenue forecast at $375,268,320 and the highest revenue forecast at $375,268,320.